293 related articles for article (PubMed ID: 34289338)
1. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.
Zarbin MA; Hill L; Maunz A; Gliem M; Stoilov I
Br J Ophthalmol; 2022 Nov; 106(11):1561-1566. PubMed ID: 34039560
[TBL] [Abstract][Full Text] [Related]
3. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis.
Patil NS; Mihalache A; Dhoot AS; Popovic MM; Muni RH; Kertes PJ
JAMA Ophthalmol; 2022 Jun; 140(6):611-622. PubMed ID: 35551359
[TBL] [Abstract][Full Text] [Related]
4. Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.
Sadda S; Holekamp NM; Sarraf D; Ebraheem A; Fan W; Hill L; Blotner S; Spicer G; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Dec; 260(12):3781-3789. PubMed ID: 35687173
[TBL] [Abstract][Full Text] [Related]
5. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
Lally DR; Hill L; Amador-Patarroyo MJ
Ophthalmol Retina; 2022 Nov; 6(11):1054-1060. PubMed ID: 35654363
[TBL] [Abstract][Full Text] [Related]
6. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
[TBL] [Abstract][Full Text] [Related]
7. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
[TBL] [Abstract][Full Text] [Related]
8. Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.
Freund KB; Staurenghi G; Jung JJ; Zweifel SA; Cozzi M; Hill L; Blotner S; Tsuboi M; Gune S
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2437-2447. PubMed ID: 35239009
[TBL] [Abstract][Full Text] [Related]
9. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
Khurana RN; Chang L; Day BM; Ghanekar A; Stoilov I
Ophthalmol Retina; 2020 Aug; 4(8):760-766. PubMed ID: 32387055
[TBL] [Abstract][Full Text] [Related]
10. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study.
Ohji M; Okada AA; Sasaki K; Moon SC; Machewitz T; Takahashi K;
Graefes Arch Clin Exp Ophthalmol; 2021 Dec; 259(12):3637-3647. PubMed ID: 34283294
[TBL] [Abstract][Full Text] [Related]
11. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
[TBL] [Abstract][Full Text] [Related]
12. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
[TBL] [Abstract][Full Text] [Related]
13. Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial.
Riedl S; Vogl WD; Waldstein SM; Schmidt-Erfurth U; Bogunović H
Ophthalmol Retina; 2022 Apr; 6(4):291-297. PubMed ID: 34922038
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database.
Martin-Pinardel R; Izquierdo-Serra J; De Zanet S; Parrado-Carrillo A; Garay-Aramburu G; Puzo M; Arruabarrena C; Sararols L; Abraldes M; Broc L; Escobar-Barranco JJ; Figueroa M; Zapata MA; Ruiz-Moreno JM; Moll-Udina A; Bernal-Morales C; Alforja S; Figueras-Roca M; Gómez-Baldó L; Ciller C; Apostolopoulos S; Mosinska A; Casaroli Marano RP; Zarranz-Ventura J;
Br J Ophthalmol; 2024 Jan; 108(2):253-262. PubMed ID: 36627173
[TBL] [Abstract][Full Text] [Related]
15. Predominantly Persistent Subretinal Fluid in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Core JQ; Pistilli M; Daniel E; Grunwald JE; Toth CA; Jaffe GJ; Hua P; Martin DF; Ying GS; Maguire MG;
Ophthalmol Retina; 2021 Oct; 5(10):962-974. PubMed ID: 34126249
[TBL] [Abstract][Full Text] [Related]
16. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
[TBL] [Abstract][Full Text] [Related]
17. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
Waldstein SM; Wright J; Warburton J; Margaron P; Simader C; Schmidt-Erfurth U
Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
[TBL] [Abstract][Full Text] [Related]
18. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
[TBL] [Abstract][Full Text] [Related]
19. IMPLICATION OF RECURRENT OR RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL.
Wickremasinghe SS; Janakan V; Sandhu SS; Amirul-Islam FM; Abedi F; Guymer RH
Retina; 2016 Jul; 36(7):1331-9. PubMed ID: 26655608
[TBL] [Abstract][Full Text] [Related]
20. Impact of Persistent Retinal Fluid in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice.
Iyer AI; Muste JC; Kalur A; Talcott KE; Singh RP
Ophthalmic Surg Lasers Imaging Retina; 2022 Jun; 53(6):317-324. PubMed ID: 35724366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
